Senti Bio Hosts Key Investor Conferences This Fall
Senti Bio's Upcoming Investor Conferences
Senti Biosciences, Inc. (NASDAQ: SNTI) is poised to engage investors this fall as the company showcases its groundbreaking advancements in biotechnology. Senti Bio, known for its innovative Gene Circuit platform, is developing next-generation cell and gene therapies. One such initiative is SENTI-202, currently in Phase 1 clinical trials, which is engineered as a Logic Gated off-the-shelf CAR-NK investigational cell therapy.
Conference Participation Details
The company has announced its participation in two significant investor conferences:
H.C. Wainwright’s 26th Annual Global Investment Conference
The event will feature presentations and one-on-one meetings, providing an excellent opportunity for investors to learn more about Senti Bio's progress. The recorded presentation will be accessible starting on September 9, 2024, at 7:00 a.m. ET.
Chardan's 8th Annual Genetic Medicines Conference
This conference will offer a fireside chat format along with the chance for one-on-one meetings. The live webcast for this event will start on September 30, 2024, at 5:00 p.m. ET.
Archived Presentations
For those unable to attend the live events, Senti Bio will provide archived replays available through their Events & Presentations section on their website for approximately 90 days post-event. Interested parties can also reach out via email for one-on-one meeting arrangements.
Exploring SENTI-202
SENTI-202 represents a promising approach to combating hematologic malignancies. It is designed to specifically target CD33 and FLT3 expressing cells, notably in conditions like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), while preserving healthy bone marrow cell integrity. The innovative therapy incorporates three key components: an activating CAR targeting both CD33 and FLT3, a protective NOT GATE allowing healthy cells to remain unharmed, and a calibrated-release IL-15 technology that enhances the efficacy and longevity of the therapy.
Currently, Senti Bio is enrolling adult patients suffering from recurrent/refractory hematologic malignancies to participate in the ongoing Phase 1 clinical trial for SENTI-202. With the anticipation of initial trial results expected by the close of 2024, the company may pave the way for a revolutionary allogeneic treatment option for AML and MDS patients.
About Senti Bio's Broader Mission
Senti Bio is devoted to developing cutting-edge therapies leveraging a proprietary synthetic biology platform known as Gene Circuits. This platform aims to create therapies that not only selectively eliminate cancer cells but also spare healthy cells. The company is working diligently to advance its wholly-owned pipeline, focusing on off-the-shelf CAR-NK cells equipped with these Gene Circuits to tackle challenging oncological conditions.
Furthermore, Senti Bio has made strides in demonstrating the versatility of its Gene Circuits technology beyond oncology through collaborations with recognized industry leaders. These partnerships are designed to broaden the scope of therapeutic applications, enhancing treatment effectiveness across various disease modalities.
Frequently Asked Questions
1. What is SENTI-202?
SENTI-202 is a CAR-NK cell therapy targeting CD33 and FLT3 expressed in malignancies like AML and MDS, focusing on preserving healthy cells.
2. When will the results of the SENTI-202 clinical trial be available?
Senti Bio expects to release initial clinical trial results for SENTI-202 by the end of 2024.
3. How can investors access the presentations from the conferences?
The presentations will be available through Senti Bio's website for approximately 90 days after the events.
4. What is the significance of the upcoming investor conferences?
These conferences provide Senti Bio with a platform to discuss their advancements and engage with potential investors and stakeholders.
5. How does Senti Bio leverage its Gene Circuit technology?
Senti Bio utilizes its Gene Circuit platform to develop therapies that enhance specificity, control, and efficacy in targeting cancer cells.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- US Dollar Index Emerges as Key Factor for European Markets
- Trinity Biotech Welcomes Adrian Donohue as CCO
- Executive Home Care Promotes Fall Prevention Awareness for Seniors
- Keywords Studios Plc: Recent Public Position Disclosure
- Simtra BioPharma Solutions Welcomes Dr. Mike Schaefers
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Optical Modulators Market Growth Metrics and Key Drivers
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
- GeoVax Labs, Inc. Announces Upcoming Investor Events!
- Kronos Bio to Showcase Research at Key Medical Conferences
- NMI Holdings, Inc. Investor Day Scheduled for November 2024
- Avenue Therapeutics Announces Participation in Investor Conferences
- Y-mAbs Therapeutics to Present at Key Investor Conferences
- TC BioPharm Expands Patient Dosing in ACHIEVE Clinical Trial
- LeNae Goolsby's Journey: Reversing Biological Age Naturally
- Strider Bikes Hosts an Exciting Adventure-Cross Race
- Enviri Corporation Prepares for Key Investor Conferences
- PDS Biotech CEO to Present at H.C. Wainwright Conference
- Processa Pharmaceuticals and Upcoming Industry Conferences
- Compass Therapeutics Engages Investors at Upcoming Events
- BioVie Secures FDA Approval for Bezisterim Long COVID Study
- Aspire Biopharma and PowerUp Combine to Innovate Drug Delivery
- NKGen Biotech Set to Showcase Innovations at Investment Conference
- Key Manufacturing PMI and ISM Data for Market Insights
- Navigating Risks for Bullish Investors this September
Recent Articles
- Top Three High-Yield Dividend Stocks to Buy Now
- Decisely Proudly Partners with Stewart-Haas Racing in NASCAR
- Cambridge Launches Family Business Leadership Programme in 2024
- Spectral Capital Launches NOOT: A Revolutionary Quantum Social Media
- Global Smart Airport Market Set to Reach 322 Billion USD by 2031
- MDWerks Partners with Green Glass Global to Boost Sales
- LM Funding America, Inc. Gears Up for H.C. Wainwright Conference
- VCI Global Secures $18 Million Contract for IPO Listings
- Callinex Begins 2024 Exploration at Pine Bay Project Initiative
- Blitz Selects Magnite as Preferred SSP for Programmatic Growth
- Earnings Reports Tuesday: Zscaler, Gitlab, Healthequity Insights
- Green Bonds Market Expected to Reach $960 Billion by 2033
- Spectral Medical Updates on Progress of Tigris Trial
- Cognition Therapeutics: Upcoming Investor Conferences Insights
- InflaRx Unveils Promising Preclinical Findings for INF904
- H World Group Limited Appoints New Chief Financial Officer
- Discover The Botanist Islay's New Distiller's Strength Gin
- Exploring AI Investment Opportunities with Palantir and AMD
- ATHA Energy's 2024 Exploration Uncovers New Mineral Trends
- Scorpio Tankers Executes Vessel Sales and Charter Agreements
- Vow ASA Insights: Recent Insider Trading Activity Reported
- Calliditas Therapeutics' Strategic Response to Asahi Kasei's Move
- American Airlines Group Inc. Faces Securities Lawsuit - AAL
- Investing in the Future: AI Stocks to Consider Now
- Turmalina Metals Corp Secures Approval for Colquemayo Project